1309PERMETIC-2 PROJECT : IMPACT OF SYSTEMATIC EGFR AND KRAS MUTATION EVALUATION BY ALTERNATIVE TESTING METHODS ON PROGRESSION-FREE (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH ADVANCED NON–SMALL-CELL LUNG CANCER (NSCLC) TREATED BY ERLOTINIB (E) IN THE IFCT ERMETIC COHORT

ABSTRACT Aim: ERMETIC is a French (IFCT) prospective study of EGFR and KRAS mutation evaluation by sequencing in patients with advanced NSCLC treated by E. The aim of the ERMETIC-2 project was to determine the prognostic impact of using alternative molecular techniques in the available tumor samples of the ERMETIC cohort. Methods: 239 patients (pts) with tumors were available for re-analyze by previously described alternative techniques (J Mol Diag 2014). Multivariate Cox model with performance status, histology, smoking status and initial number of metastatic sites was used for prognostic analysis. Results: Population included 59% of adenocarcinoma, 37% of women and 19% of non-smokers. Overall mutation rate is 46%: 31 EGFR mutations (13%) and 78 KRAS mutations (33%); 40 new mutations compared to previous study were found: 9 EGFR and 31 KRAS. In the ERMETIC 2 cohort, OS and PFS remained significantly (global test p Conclusions: 1. KRAS but not EGFR mutations were detected in higher proportion by alternative molecular techniques compared to sequencing. 2. KRAS mutations identified by more sensitive technique did not identified a group of patients with a different prognostic. Disclosure: All authors have declared no conflicts of interest.